Literature DB >> 22869710

First-order rate-determining aggregation mechanism of p53 and its implications.

GuoZhen Wang1, Alan R Fersht.   

Abstract

Aggregation of p53 is initiated by first-order processes that generate an aggregation-prone state with parallel pathways of major or partial unfolding. Here, we elaborate the mechanism and explore its consequences, beginning with the core domain and extending to the full-length p53 mutant Y220C. Production of large light-scattering particles was slower than formation of the Thioflavin T-binding state and simultaneous depletion of monomer. EDTA removes Zn(2+) to generate apo-p53, which aggregated faster than holo-p53. Apo-Y220C also aggregated by both partial and major unfolding. Apo-p53 was not an obligatory intermediate in the aggregation of holo-p53, but affords a parallel pathway that may be relevant to oncogenic mutants with impaired Zn(2+) binding. Full-length tetrameric Y220C formed the Thioflavin T-binding state with similar rate constants to those of core domain, consistent with a unimolecular initiation that is unaffected by neighboring subunits, but very slowly formed small light-scattering particles. Apo-Y220C and aggregated holo-Y220C had little, if any, seeding effect on the initial polymerization of holo-Y220C (measured by Thioflavin T binding), consistent with initiation being a unimolecular process. But apo-Y220C and aggregated holo-Y220C accelerated somewhat the subsequent formation of light-scattering particles from holo-protein, implying coaggregation. The implications for cancer cells containing wild-type and unstable mutant alleles are that aggregation of wild-type p53 (or homologs) might not be seeded by aggregated mutant, but it could coaggregate with p53 or other cellular proteins that have undergone the first steps of aggregation and speed up the formation of microscopically observable aggregates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869710      PMCID: PMC3427100          DOI: 10.1073/pnas.1211557109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding.

Authors:  Jennifer M Andrews; Christopher J Roberts
Journal:  J Phys Chem B       Date:  2007-06-16       Impact factor: 2.991

Review 2.  Amyloid formation by globular proteins under native conditions.

Authors:  Fabrizio Chiti; Christopher M Dobson
Journal:  Nat Chem Biol       Date:  2009-01       Impact factor: 15.040

3.  Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.

Authors:  Rainer Wilcken; GuoZhen Wang; Frank M Boeckler; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

4.  Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.

Authors:  Jie Xu; Joke Reumers; José R Couceiro; Frederik De Smet; Rodrigo Gallardo; Stanislav Rudyak; Ann Cornelis; Jef Rozenski; Aleksandra Zwolinska; Jean-Christophe Marine; Diether Lambrechts; Young-Ah Suh; Frederic Rousseau; Joost Schymkowitz
Journal:  Nat Chem Biol       Date:  2011-03-27       Impact factor: 15.040

5.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.

Authors:  A N Bullock; J Henckel; A R Fersht
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

6.  Thermodynamic stability of wild-type and mutant p53 core domain.

Authors:  A N Bullock; J Henckel; B S DeDecker; C M Johnson; P V Nikolova; M R Proctor; D P Lane; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

7.  Structure, function, and aggregation of the zinc-free form of the p53 DNA binding domain.

Authors:  James S Butler; Stewart N Loh
Journal:  Biochemistry       Date:  2003-03-04       Impact factor: 3.162

8.  A structural role for metal ions in the "wild-type" conformation of the tumor suppressor protein p53.

Authors:  P Hainaut; J Milner
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

9.  Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.

Authors:  Hwee Ching Ang; Andreas C Joerger; Sebastian Mayer; Alan R Fersht
Journal:  J Biol Chem       Date:  2006-06-05       Impact factor: 5.157

10.  Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer.

Authors:  Eviatar Natan; Cetin Baloglu; Kevin Pagel; Stefan M V Freund; Nina Morgner; Carol V Robinson; Alan R Fersht; Andreas C Joerger
Journal:  J Mol Biol       Date:  2011-03-30       Impact factor: 5.469

View more
  29 in total

1.  Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.

Authors:  Rainer Wilcken; GuoZhen Wang; Frank M Boeckler; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-06       Impact factor: 11.205

2.  Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Authors:  Jiangtao Lei; Ruxi Qi; Guanghong Wei; Ruth Nussinov; Buyong Ma
Journal:  Phys Chem Chem Phys       Date:  2016-03-21       Impact factor: 3.676

3.  Orthogonal high-throughput thermal scanning method for rank ordering protein formulations.

Authors:  Vishal C Nashine; Andrew M Kroetsch; Erinc Sahin; Rong Zhou; Monica L Adams
Journal:  AAPS PharmSciTech       Date:  2013-09-04       Impact factor: 3.246

Review 4.  Salvation of the fallen angel: Reactivating mutant p53.

Authors:  Yang Li; Zhuoyi Wang; Yuchen Chen; Robert B Petersen; Ling Zheng; Kun Huang
Journal:  Br J Pharmacol       Date:  2019-02-28       Impact factor: 8.739

5.  p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.

Authors:  Saikat Ghosh; Shimul Salot; Shinjinee Sengupta; Ambuja Navalkar; Dhiman Ghosh; Reeba Jacob; Subhadeep Das; Rakesh Kumar; Narendra Nath Jha; Shruti Sahay; Surabhi Mehra; Ganesh M Mohite; Santanu K Ghosh; Mamata Kombrabail; Guruswamy Krishnamoorthy; Pradip Chaudhari; Samir K Maji
Journal:  Cell Death Differ       Date:  2017-06-23       Impact factor: 15.828

6.  Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.

Authors:  L Palanikumar; Laura Karpauskaite; Mohamed Al-Sayegh; Ibrahim Chehade; Maheen Alam; Sarah Hassan; Debabrata Maity; Liaqat Ali; Mona Kalmouni; Yamanappa Hunashal; Jemil Ahmed; Tatiana Houhou; Shake Karapetyan; Zackary Falls; Ram Samudrala; Renu Pasricha; Gennaro Esposito; Ahmed J Afzal; Andrew D Hamilton; Sunil Kumar; Mazin Magzoub
Journal:  Nat Commun       Date:  2021-06-25       Impact factor: 14.919

7.  A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.

Authors:  Alice Soragni; Deanna M Janzen; Lisa M Johnson; Anne G Lindgren; Anh Thai-Quynh Nguyen; Ekaterina Tiourin; Angela B Soriaga; Jing Lu; Lin Jiang; Kym F Faull; Matteo Pellegrini; Sanaz Memarzadeh; David S Eisenberg
Journal:  Cancer Cell       Date:  2015-12-31       Impact factor: 31.743

Review 8.  Mutations, protein homeostasis, and epigenetic control of genome integrity.

Authors:  Jinglin Lucy Xie; Daniel F Jarosz
Journal:  DNA Repair (Amst)       Date:  2018-08-23

9.  SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Authors:  Luca Malcovati; Mohsen Karimi; Elli Papaemmanuil; Ilaria Ambaglio; Martin Jädersten; Monika Jansson; Chiara Elena; Anna Gallì; Gunilla Walldin; Matteo G Della Porta; Klas Raaschou-Jensen; Erica Travaglino; Klaus Kallenbach; Daniela Pietra; Viktor Ljungström; Simona Conte; Emanuela Boveri; Rosangela Invernizzi; Richard Rosenquist; Peter J Campbell; Mario Cazzola; Eva Hellström Lindberg
Journal:  Blood       Date:  2015-05-08       Impact factor: 22.113

10.  Variable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties.

Authors:  Ankush Garg; Jagadish Prasad Hazra; Malay Kumar Sannigrahi; Sabyasachi Rakshit; Sharmistha Sinha
Journal:  Biophys J       Date:  2019-12-21       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.